WHO
REGULATORY UPDATE
42nd Invitation to manufacturers of Active Pharmaceutical Ingredients (API) to submit an Expression of Interest (EOI) for API evaluation to the WHO Prequalification Unit (PQT)
Published: 9/28/2026Detected: 8/13/2026
Summary preview
Adds hydroxyurea API for products used to treat sickle cell disease to the WHO Prequalification Unit (PQT) expression of interest (EOI) pathway for API evaluation.
Get the full analysis, free
Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.
Create free accountrare_diseases
hematology
manufacturing
quality
#WHO prequalification
#PQT
#API evaluation
#Expression of Interest (EOI)
#hydroxyurea
Official Source Document Source Verified
Access the original document directly from WHO.
More from WHO
- New Deadline for Submission: Request for Quotations (RFQ) from interested Notified Bodies - WHO Prequalification Assessment for Medical Devices10/2/2026
- PQT/AMD newsletter - Q3 2026, Issue 54 is now available10/2/2026
- PQ Webinar: Launch of WHO Prequalification of Medical Devices10/2/2026
- New EUL listing10/2/2026
- Prequalification of In Vitro Diagnostics: Scope Expansion10/2/2026